DRMA: Rega marang dodolan Dermata

The price-to-sales ratio demonstrates the market valuation of Dermata Therapeutics (DRMA), where the value is fixed at 46.70. The scientific team is developing a unique drug delivery platform to combat rosacea and acne. Dermata Therapeutics (DRMA) is creating innovative topical agents based on freshwater sponges, currently undergoing FDA reviews. Patents for a mechanical therapy method provide a competitive advantage, determining the future profitability of the business.

DRMA: Rasio rega marang pendapatan Dermata Therapeutics, Inc. 12.11.2026 - 13.11.2026

Dermata (DRMA) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:

Kurs saham dermatarx.com|DRMA - Prakiraan konsensus analis

- informasi kapitalisasi pasar:

Nilai pasar Dermata|DRMA - Nilai Total Perusahaan

- data nilai buku modal saham:

Nilai Akuntansi Saham Dermata Therapeutics|DRMA - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Aset Bersih dermatarx.com|DRMA - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal Dermata Therapeutics|DRMA - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal Dermata Corp|DRMA - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Dermata|DRMA - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Dermata Therapeutics|Rasio likuiditas perantara dermatarx.com

- informasi bathi lan kelipatan valuasi:

DRMA - Bathi resik|Penghasilan resik sing dikarepake Dermata Therapeutics|DRMA - Pangali P/E|Rasio prakiraan rega marang bathi Dermata Therapeutics Inc|DRMA - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Dermata|DRMA - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Dermata Therapeutics|DRMA - Bathi saben saham sajrone rolas wulan pungkasan|Dinamika bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan dermatarx.com|DRMA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Dermata Therapeutics

- data total pendapatan lan volume dodolan:

DRMA - Dodolan perusahaan|Prakiraan volume dodolan dermatarx.com|DRMA - Kapitalisasi marang pendapatan|Rasio rega marang pendapatan sing dikarepake Dermata

Analisis umum perusahaan:DRMA dermatarx.com

Produk mawa merek Dermata Therapeutics Inc

Dermata Therapeutics' reputation for developing safe acne and rosacea treatments drives high brand equity, which investors evaluate via the price-to-sales ratio. This metric measures the cost per unit of revenue, allowing the P/S levels on the chart to determine the asset's degree of overvaluation and identify the exhaustion of business growth drivers in a timely manner.

Karo sapa Dermata Therapeutics saingan

krystalbio.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S APGE (Apogee Therapeutics, Inc.)|Arcutis (ARQT) - Rega marang dodolan|VCEL - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ORKA (Oruka Pharma)|sanaramedtech.com (SMTI) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan DBV Technologies|SLSN (Solesence Beauty) - Multiplikator P/S|Multiplikator P/S Journey Medical Corp.|Kapitalisasi marang pendapatan FBRX (Forte Biosciences, Inc)|Kapitalisasi marang volume dodolan EMPG|Multiplikator P/S SLGL (Sol-Gel Technologies)|Multiplikator P/S AXIL Brands Inc AXIL|MDCX: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan VRCA (Verrica Pharmaceuticals)|HOTH (hoththerapeutics.com) - Kapitalisasi marang pendapatan|BFRI: Kapitalisasi marang volume dodolan|VYNE (VYNE Therapeutics, Inc.) - Multiplikator P/S|SNOA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QNRX|AZTR - Rega marang dodolan|Rasio rega marang pendapatan Elevai Skincare ELAB|Rasio kapitalisasi pasar marang pendapatan RVNC